Article Text

Download PDFPDF

Call for ensuring cancer care continuity during COVID-19 pandemic
  1. Marco Tagliamento1,2,
  2. Matteo Lambertini1,3,
  3. Carlo Genova2,
  4. Emanuela Barisione4,
  5. Andrea De Maria5,6,
  6. Marco Grosso4,
  7. Francesca Poggio2,
  8. Stefano Vagge7,
  9. Francesco Boccardo1,3,
  10. Paolo Pronzato2,
  11. Lucia Del Mastro1,2
  1. 1 Department of Internal Medicine and Medical Specialties (Di.M.I.), School of Medicine, University of Genoa, Genoa, Italy
  2. 2 Department of Medical Oncology, U.O.C. Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  3. 3 Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  4. 4 Interventional Pneumology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  5. 5 Department of Health Sciences, University of Genoa, Genoa, Italy
  6. 6 Infectious Diseases Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  7. 7 Department of Radiation Oncology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
  1. Correspondence to Dr Marco Tagliamento; tagliamento.marco{at}gmail.com

Statistics from Altmetric.com

On 11 March 2020, WHO declared the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be a pandemic, and the related syndrome was then named coronavirus disease 2019 (COVID-19). As of 6 April 2020, 1 211 203 confirmed cases and 67 596 deaths have been recorded worldwide, Italy being one of the worst affected countries so far.

Frail patients, such as elderly people or those with underlying conditions, are at higher risk of complications related to COVID-19.1 The burden of SARS-CoV-2 infection among patients with cancer has not been established yet, but their potential immunocompromised state is of concern.2 Preliminary data suggest an increased risk of developing infection-related severe events (ie, admission to the intensive care unit, mechanical ventilation or death) in the case of antitumour treatment administration within two weeks before COVID-19 diagnosis. Therefore, the authors suggested that treatment strategies likely to cause immunosuppression should be avoided or retained at decreased dosages.3 The Italian directives for the management of onco-haematological patients on therapy during the COVID-19 pandemic recommend considering treatment delays on a case-by-case basis, taking into account the characteristics of the patient and the disease.4

By reporting consecutive cases of SARS-CoV-2 infection among patients with cancer treated at our centre, we aim to call for the need for adequate and dedicated facilities to manage cancer care after infection with SARS-CoV-2. Between 10 March and 6 April, 17 patients with a median age of 68 years (range 46–89) tested positive for SARS-CoV-2 by RT-PCR on nasopharyngeal swab. Among these patients, 16 (94%) had symptoms related to COVID-19; eight had severe respiratory symptoms, and 13 (76%) were admitted to hospital (table 1). At a median follow-up of 15 days since the confirmed diagnosis of SARS-CoV-2 infection, the case fatality rate was 24%: four patients out of 17 died due to severe COVID-19, two of whom were on oncological follow-up (ie, off therapy). All 12 patients (100%) who were on therapy in different settings have experienced treatments delays or permanent discontinuation, and one patient did not undergo the scheduled diagnostic procedures. Notably, we had patients with mild symptoms or no symptoms who had antineoplastic treatments delayed; these treatments had a curative purpose as well as a high probability of long-term disease control (eg, neoadjuvant chemotherapy for locally advanced triple-negative breast cancer, chemo-radiotherapy for limited-stage small-cell lung cancer, first-line ALK inhibitor for advanced lung adenocarcinoma). Similarly, other patients currently in hospital with mild COVID-19 syndrome might need to resume their therapeutic plan after complete resolution of their symptoms despite SARS-CoV-2 still being detectable potentially for weeks. According to hospital guidelines, recovery is defined by two consecutive negative RT-PCR tests obtained at least 24 hours apart, performed at least 15 days after the resolution of signs and symptoms. Moreover, if we assume that there is a non-negligible proportion of asymptomatic cases that are a potential source of transmission to other patients with cancer,5 we estimate that the number of unrecognised patients with SARS-CoV-2 infection might be higher than expected. Widespread testing for SARS-CoV-2 among patients with cancer and their healthcare providers could also help to control the potential negative consequences of this outbreak on cancer care. Based on our preliminary experience, we are opening a new unit that will work as a regional cancer hub for the care of patients with cancer affected by COVID-19 within a multidisciplinary team. With the current uncertainty, the important aim behind this decision is to ensure continuity of care to those selected patients who can reasonably receive oncological treatments in spite of SARS-CoV-2 positivity, balancing the risks associated with the infection and the disruption of proper antineoplastic strategies.

Table 1

Patient’s, disease and treatment characteristics

References

View Abstract

Footnotes

  • Twitter @tagliamento_m, @matteolambe

  • Contributors All the authors equally contributed to this work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Marco Tagliamento declares travel, accommodation, expenses supported by Roche, Bristol-Myers Squibb, Astra Zeneca, Takeda, and activity as Medical Writer supported by Novartis outside the submitted work. Matteo Lambertini acted as consultant for Roche and Ely Lilly, and received speaker honoraria from Roche, Takeda and Theramex outside the submitted work. Carlo Genova received honoraria from Astra Zeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Roche outside the submitted work. Francesca Poggio declares travel, accommodations, expenses supported by Takeda, Ely Lilly, and received honoraria from Merck Sharp & Dohme, Ely Lilly, Novartis outside the submitted work. Lucia Del Mastro reports personal fees from Roche, Pfeizer, Ipsen, Eli Lilly, Novartis, Takeda, Merck Sharp & Dohme, Genomic Health, Seattle Genetics, and non-financial support from Celgene outside the submitted work. The other authors declare no competing interests.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.